Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00073892 · ClinicalTrials.gov registry record · Phase 1
PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma
A Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Melanoma (Skin), sponsored by Cellxpert Biotechnology.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 5
- Study locations
NCT00073892: Completed Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Melanoma (Skin), sponsored by Cellxpert Biotechnology.
NCT00073892 is a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Melanoma (Skin) that has completed, run by Cellxpert Biotechnology. The registered enrollment target is 44 participants, below the 501-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (91% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00073892, a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Melanoma (Skin), has completed, sponsored by Cellxpert Biotechnology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 5
- Study locations
Study Summary
RATIONALE: PI-88 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of PI-88 in treating patients who have an advanced malignancy (cancer) or stage IV melanoma.
Primary Outcome
non-progression rate (objective response or stable disease)
Conditions Studied
Interventions
- DRUG PI-88
Study Locations (5)
Colorado
- University of Colorado Cancer Center at University of Colorado Health Sciences Center - Aurora
Queensland
- Princess Alexandra Hospital - Brisbane
South Australia
- Queen Elizabeth Hospital - Woodville
Victoria
- Alfred Hospital - Melbourne
Western Australia
- Sir Charles Gairdner Hospital - Perth - Perth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2004-01 |
| Est. Completion | 2005-11 |
| Phase | Phase 1 |
What the finished NCT00073892 record still lists
NCT00073892 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 501-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with Unspecified Adult Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 1 intervention - of which PI-88 is the first listed.
NCT00073892 lists 5 locations in 5 states (Colorado, Queensland, South Australia).
Frequently Asked Questions
What is clinical trial NCT00073892 about?
NCT00073892 is a clinical study titled "PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma". RATIONALE: PI-88 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of PI-88 in treating patients who have an advanced malignancy (cancer) or stage IV melanoma.
What is the current status of trial NCT00073892?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2004-01. Estimated completion is 2005-11.
What conditions does trial NCT00073892 study?
This clinical trial studies the following conditions: Unspecified Adult Solid Tumor, Protocol Specific, Melanoma (Skin).
What interventions are being tested in trial NCT00073892?
The interventions under investigation include: PI-88 (DRUG).
Who is sponsoring clinical trial NCT00073892?
This trial is sponsored by Cellxpert Biotechnology, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00073892 being conducted?
This trial has 5 study locations across Colorado, Queensland, South Australia, Victoria, Western Australia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unspecified Adult Solid Tumor, Protocol Specific
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00073892's enrollment target sits among peer trials
44 37th of 83 higher than 44 of 83 other Unspecified Adult Solid Tumor, Protocol Specific trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Unspecified Adult Solid Tumor, Protocol Specific trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists
ACTIVE NOT RECRUITING · Phase 1
-
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
COMPLETED · Phase 1
-
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
BMS-599626 in Treating Patients With Metastatic Solid Tumors
COMPLETED · Phase 1
-
Indole-3-Carbinol in Preventing Cancer in Healthy Participants
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia